NCT01119339View on ClinicalTrials.gov

Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Psoriasis
Interventions
DRUG

LAS 41004

LAS 41004 dosage 1, once daily

DRUG

LAS 41004

LAS 41004 dosage 2, once daily

DRUG

LAS 41004

LAS 41004 dosage 3, once daily

DRUG

LAS 41004

LAS 41004 dosage 4, once daily

DRUG

LAS 41004

LAS 41004 , dosage 5, once daily

DRUG

LAS 41004 dosage 6

LAS 41004, dosage 6, once daily

DRUG

Placebo

Placebo, once daily

DRUG

Reference

Reference, once daily

Trial Locations (1)

15831

Almirall Investigational Sites#1, Mahlow

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY